Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

WarrenDouglasTrader Aug. 3 at 4:39 AM

$SCYX Mkt cap 26mm, they have over 40mm in cash…..positive scy-247 could trigger a buyout for $2-3

0 · Reply

LemuelPitkin Aug. 3 at 4:23 AM

$SCYX phase 1 data/ is simply dosing and safety.

1 · Reply

WarrenDouglasTrader Aug. 3 at 2:05 AM

$SCYX Scy-247 data expected “Q3 2025”…..thats any time in next 7 weeks! Lets gooooo! Knock it out of park, tell GSK to suck it, and go get a real partner or buyer for scy-247!

0 · Reply

Joe401 Aug. 2 at 9:18 PM

$SCYX once the scy-247 data is out this is gong to run up hard. I'm still keeping my eoy price at 2.00. 20 dollar stick in three years

1 · Reply

WarrenDouglasTrader Aug. 2 at 6:04 PM

$SCYX Anyone know when scy-247 data is due out?

0 · Reply

LemuelPitkin Aug. 1 at 8:22 PM

$SCYX it is quite gratifying to hear that enormous grifters failed to leverage the court system to extract money from the existing investors.

1 · Reply

btm811 Aug. 1 at 4:42 PM

$SCYX Haha, of course the only news surrounding this piece of shit these days is them fucking a shareholder over, but this time, in a court of law!

0 · Reply

pantarei Aug. 1 at 8:37 AM

$SCYX https://www.law360.com/healthcare-authority/deals-corporate-governance/articles/2371704/biotech-co-beats-investor-suit-over-antifungal-drug-recall

1 · Reply

pantarei Aug. 1 at 8:35 AM

$SCYX https://www.pacermonitor.com/public/case/51294533/FELDMAN_v_SCYNEXIS,_INC_et_al

0 · Reply

WarrenDouglasTrader Jul. 31 at 8:22 PM

$SCYX Honestly, wtf is going on with this? I guess all that is left is scy-247 data, cant get here fast enough.

0 · Reply

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Mar 12, 2025, 5:08 PM EDT - 5 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 9 months ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024, 8:00 AM EDT - 10 months ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 10 months ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 2, 2024, 10:04 AM EDT - 1 year ago

Scynexis: Update Following Restructuring Of GSK Deal

Mar 28, 2024, 4:01 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Jan 29, 2024, 5:15 PM EST - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 8, 2024, 4:00 AM EST - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 5, 2024, 8:30 AM EST - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 4, 2024, 7:00 AM EST - 1 year ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 28, 2023, 9:00 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:46 PM EST - 1 year ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:15 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 29, 2023, 7:50 PM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 1 year ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 1 year ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 1 year ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 15, 2023, 1:15 PM EST - 1 year ago

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

Nov 13, 2023, 5:17 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 24, 2023, 8:00 AM EDT - 1 year ago

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Oct 6, 2023, 5:20 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors

WarrenDouglasTrader Aug. 3 at 4:39 AM

$SCYX Mkt cap 26mm, they have over 40mm in cash…..positive scy-247 could trigger a buyout for $2-3

0 · Reply

LemuelPitkin Aug. 3 at 4:23 AM

$SCYX phase 1 data/ is simply dosing and safety.

1 · Reply

WarrenDouglasTrader Aug. 3 at 2:05 AM

$SCYX Scy-247 data expected “Q3 2025”…..thats any time in next 7 weeks! Lets gooooo! Knock it out of park, tell GSK to suck it, and go get a real partner or buyer for scy-247!

0 · Reply

Joe401 Aug. 2 at 9:18 PM

$SCYX once the scy-247 data is out this is gong to run up hard. I'm still keeping my eoy price at 2.00. 20 dollar stick in three years

1 · Reply

WarrenDouglasTrader Aug. 2 at 6:04 PM

$SCYX Anyone know when scy-247 data is due out?

0 · Reply

LemuelPitkin Aug. 1 at 8:22 PM

$SCYX it is quite gratifying to hear that enormous grifters failed to leverage the court system to extract money from the existing investors.

1 · Reply

btm811 Aug. 1 at 4:42 PM

$SCYX Haha, of course the only news surrounding this piece of shit these days is them fucking a shareholder over, but this time, in a court of law!

0 · Reply

pantarei Aug. 1 at 8:37 AM

$SCYX https://www.law360.com/healthcare-authority/deals-corporate-governance/articles/2371704/biotech-co-beats-investor-suit-over-antifungal-drug-recall

1 · Reply

pantarei Aug. 1 at 8:35 AM

$SCYX https://www.pacermonitor.com/public/case/51294533/FELDMAN_v_SCYNEXIS,_INC_et_al

0 · Reply

WarrenDouglasTrader Jul. 31 at 8:22 PM

$SCYX Honestly, wtf is going on with this? I guess all that is left is scy-247 data, cant get here fast enough.

0 · Reply

whob007 Jul. 31 at 6:33 PM

$SCYX per Chat GBT Contractual Trigger: SCYNEXIS believes it met the milestone terms by restarting dosing in May 2025, which, under their licensing deal, triggered a $10 million milestone, with another $20 million due within six months. GSK Dispute: GSK disputes this, potentially arguing that the conditions for the milestone weren't fully satisfied (e.g., trial protocol amendments, FDA engagement, or clinical hold language). Materiality to SCYX: This payment is financially significant to SCYX, especially given its small-cap biotech status and reliance on partner funding for its clinical program. Legal vs. Strategic Risk for GSK: GSK risks reputational and partnership damage if seen as unfairly withholding payments, especially in the context of antimicrobial resistance (AMR) — a politically and socially sensitive space.

1 · Reply

whob007 Jul. 31 at 6:26 PM

$SCYX GSK owes SCYNEXIS $30 million related to the Phase 3 MARIO trial for invasive candidiasis. This amount includes a disputed $10 million milestone payment triggered by the trial's dosing resumption in May 2025, with an additional $20 million expected in six months. This situation has been quite contentious between the two companies. The 30 million is more than SCYX current market Cap

1 · Reply

SnapCrackleStop Jul. 31 at 5:18 PM

$SCYX To clarify. The $GSK presentation simply repeated what they have already done. $GSK is refusing to fund the MARIO trial. Why? They are continuing to market Brexafemme For V V C More bullying by the billion dollar baby Glaxo $

1 · Reply

pjinvestmentco Jul. 31 at 12:09 PM

$SCYX GSK did not include Brexafemme in yesterday's earnings report...no mention which means they most likely will sell or give the drug back to Scynexis

1 · Reply

Kingbk0911 Jul. 30 at 5:34 PM

$SCYX been holding for years down 93% 😑

1 · Reply

pjinvestmentco Jul. 29 at 2:28 PM

$SCYX 65 cents coming

0 · Reply

Valueisoutthere Jul. 29 at 1:51 PM

$SCYX biotech red day, still bullish over the long haul….I can wait

0 · Reply

Pommy1 Jul. 28 at 10:27 PM

$SCYX omg this is still not delisted.3 months over under a dollar

1 · Reply

btm811 Jul. 28 at 8:43 PM

$SCYX you know, even a simple acknowledgment of how shitty it feels to be a stockholder these last few months/Years would be nice. Any sort of acknowledgment at all from management

1 · Reply

pjinvestmentco Jul. 28 at 12:11 PM

$SCYX David CEO if he ever did a Conference call with shareholders and analysts

0 · Reply

DataJim Jul. 25 at 7:34 PM

$SCYX So tempted to sell some of this to buy more $TLSA This is the only thing I have that I could sell at a loss and I can’t add any more taxable income this year. The issue is I know this is worth way more than $.75 a share.

1 · Reply

LemuelPitkin Jul. 25 at 5:38 PM

$SCYX AI Overview Based on the available information, GSK's financials appear to be performing well this year, particularly in its Specialty Medicines segment, but facing challenges in Vaccines sales. Here's a summary of the key points: Positive Indicators: Strong overall performance in 2023 and early 2024: GSK reported excellent performance in 2023 with robust growth in sales, profits, and earnings. This momentum continued into Q1 2024, with strong results and improved outlook for the year. The company also delivered a strong Q2 2024 performance, reflected in upgraded 2024 guidance. Specialty Medicines leading growth: The Specialty Medicines unit has demonstrated consistent strong performance, particularly with successful new product launches in oncology and long-acting HIV medicines. In the first quarter of 2025, Specialty Medicines sales rose by 17%... Upgraded long-term outlook: GS Strong R&D pipeline: GSK continues to strengthen its R&D pipeline with positive phase III trial results...

0 · Reply

Market Cap	26.58M
Revenue (ttm)	3.75M
Net Income (ttm)	-21.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-567.73%
Debt to Equity Ratio	0.00

Volume	125,000
Avg Vol	182,048
Day's Range	N/A - N/A
Shares Out	39.02M
Stochastic %K	9%
Beta	1.64
Analysts	Strong Sell
Price Target	$4.67